RDVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RDVT is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock is technically strong, but it is also extended and overbought, while recent institutional/hedge fund selling and a lower analyst price target create a mixed setup. Since the user is impatient and not waiting for an ideal pullback, my direct view is to hold off on buying at this price and wait for a better entry.
RDVT shows a clear bullish trend: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, and MACD histogram is positive and expanding, which confirms upward momentum. However, RSI_6 is 91.503, which is extremely overbought and suggests the recent move may be stretched. Price at 65.78 is just above the pivot (60.002) and near first resistance (R1 65.656), so upside from here looks limited short term unless it breaks cleanly above resistance. Overall trend is bullish, but the current entry is not attractive for a long-term beginner at this level.
["Bullish moving average structure (SMA_5 > SMA_20 > SMA_200)", "MACD histogram is positive and expanding, supporting momentum continuation", "Strong call skew in options data suggests bullish trader sentiment", "Analyst still maintains a Buy rating despite cutting the target", "Analyst believes 2026 and 2027 estimates are achievable or beatable"]
["RSI is extremely overbought at 91.503, making the stock stretched at current levels", "Hedge funds are selling, with selling amount up 508.36% last quarter", "Analyst price target was lowered from $75 to $65, which is below the current price", "No recent news catalyst in the last week", "No recent congress trading data or insider buying support", "Short-term pattern analysis suggests muted next-week and next-month returns"]
No usable latest-quarter financial snapshot was provided due to an error, so I cannot assess the most recent quarter season directly. Based on the available analyst commentary, Red Violet’s 2026 and 2027 estimates are considered achievable, which implies confidence in continued operating performance, but there is no current quarterly revenue or earnings data here to confirm growth acceleration.
B. Riley lowered its price target on Red Violet to $65 from $75 and kept a Buy rating. That is a notable trim in valuation expectations, and the new target is slightly below the current price, which weakens the near-term upside case. Wall Street’s pros view is still constructive on the business and its earnings power, while the cons view is that the stock has already run ahead of the revised target and is vulnerable after recent SaaS-sector fear-driven selling. Overall analyst tone remains positive, but less compelling than before.
